Pharmacology Mastery Test: 2026
Curriculum Edition||Questions And
Answers With Rationales/Graded
A+/2026 Update/100% Correct
/Instant Download
Total Questions: 85
Time Limit: 90 minutes
Passing Score: 75%
Instructions: Select the best answer. Correct answers are highlighted in bold.
Each question includes a rationale based on the latest 2026 guidelines (FDA,
EMA, WHO, ASHP).
Section 1: Pharmacokinetics & Pharmacodynamics (Qs 1–12)
1. A drug with zero-order kinetics:
• A) Eliminates a constant percentage per hour
• B) Eliminates a constant amount per hour
• C) Has a half-life independent of dose
• D) Follows first-order metabolism at low doses
Rationale: Zero-order kinetics (e.g., phenytoin, high-dose alcohol) → constant
amount cleared per time. Half-life changes with dose.
2. Which phase of drug metabolism involves conjugation (e.g.,
glucuronidation)?
• A) Phase I (oxidation)
• B) Phase II (synthetic)
• C) Phase III (elimination)
, • D) Absorption phase
Rationale: Phase II – conjugation adds polar groups (glucuronide, sulfate) for
renal excretion.
3. Bioavailability (F) of an IV drug is always:
• A) 100%
• B) Depends on protein binding
• C) Depends on hepatic extraction
• D) 50% for most drugs
Rationale: IV administration bypasses absorption → F = 1.0 (100%).
4. A weak acid drug (pKa 4.4) is placed in stomach fluid (pH 1.4). It will be
mostly:
• A) Non-ionized, readily absorbed
• B) Ionized, poorly absorbed
• C) Trapped in the stomach
• D) Bound to food proteins
Rationale: pH < pKa → weak acid is protonated (non-ionized) → lipid-soluble →
absorbed. Ion trapping reversed in basic pH.
5. The volume of distribution (Vd) of a drug is 0.07 L/kg. This suggests the
drug:
• A) Is confined to plasma
• B) Accumulates in fat
• C) Crosses the blood-brain barrier
• D) Is highly tissue bound
Rationale: Vd ~0.05–0.1 L/kg = plasma volume only (e.g., warfarin, large plasma
protein-bound).
6. Which statement about drug half-life (t½) is correct (2026 update)?
• A) t½ determines dosing frequency for all drugs
, • B) t½ is constant in first-order elimination
• C) t½ is independent of clearance in zero-order
• D) t½ increases with first dose only
Rationale: First-order kinetics → constant fraction eliminated → constant t½
regardless of dose.
7. An agonist with high efficacy but low potency:
• A) Produces low maximal response even at high dose
• B) Requires high dose to reach maximum effect
• C) Binds irreversibly to receptors
• D) Blocks receptor without activation
Rationale: Potency = dose needed for effect (low potency = high dose). Efficacy =
max effect.
8. The therapeutic index (TI) is calculated as:
• A) TD50/ED50 (toxic dose 50 / effective dose 50)
• B) TD50/ED50 is correct but TI usually = LD50/ED50 in animals
• C) ED50/TD50
• D) Cmax/Tmax
Rationale: TI = LD50/ED50 (preclinical) or TD50/ED50 (clinical). Narrow TI =
low safety margin (e.g., digoxin, warfarin).
9. Enterohepatic recirculation results in:
• A) Prolonged drug action due to reabsorption
• B) Complete renal excretion
• C) Reduced plasma protein binding
• D) First-pass metabolism avoidance
Rationale: Drug (e.g., estrogen, morphine) excreted in bile → hydrolyzed in gut
→ reabsorbed → secondary peak plasma level.
10. Which drug is a prodrug requiring hepatic activation (2026 example)?
Curriculum Edition||Questions And
Answers With Rationales/Graded
A+/2026 Update/100% Correct
/Instant Download
Total Questions: 85
Time Limit: 90 minutes
Passing Score: 75%
Instructions: Select the best answer. Correct answers are highlighted in bold.
Each question includes a rationale based on the latest 2026 guidelines (FDA,
EMA, WHO, ASHP).
Section 1: Pharmacokinetics & Pharmacodynamics (Qs 1–12)
1. A drug with zero-order kinetics:
• A) Eliminates a constant percentage per hour
• B) Eliminates a constant amount per hour
• C) Has a half-life independent of dose
• D) Follows first-order metabolism at low doses
Rationale: Zero-order kinetics (e.g., phenytoin, high-dose alcohol) → constant
amount cleared per time. Half-life changes with dose.
2. Which phase of drug metabolism involves conjugation (e.g.,
glucuronidation)?
• A) Phase I (oxidation)
• B) Phase II (synthetic)
• C) Phase III (elimination)
, • D) Absorption phase
Rationale: Phase II – conjugation adds polar groups (glucuronide, sulfate) for
renal excretion.
3. Bioavailability (F) of an IV drug is always:
• A) 100%
• B) Depends on protein binding
• C) Depends on hepatic extraction
• D) 50% for most drugs
Rationale: IV administration bypasses absorption → F = 1.0 (100%).
4. A weak acid drug (pKa 4.4) is placed in stomach fluid (pH 1.4). It will be
mostly:
• A) Non-ionized, readily absorbed
• B) Ionized, poorly absorbed
• C) Trapped in the stomach
• D) Bound to food proteins
Rationale: pH < pKa → weak acid is protonated (non-ionized) → lipid-soluble →
absorbed. Ion trapping reversed in basic pH.
5. The volume of distribution (Vd) of a drug is 0.07 L/kg. This suggests the
drug:
• A) Is confined to plasma
• B) Accumulates in fat
• C) Crosses the blood-brain barrier
• D) Is highly tissue bound
Rationale: Vd ~0.05–0.1 L/kg = plasma volume only (e.g., warfarin, large plasma
protein-bound).
6. Which statement about drug half-life (t½) is correct (2026 update)?
• A) t½ determines dosing frequency for all drugs
, • B) t½ is constant in first-order elimination
• C) t½ is independent of clearance in zero-order
• D) t½ increases with first dose only
Rationale: First-order kinetics → constant fraction eliminated → constant t½
regardless of dose.
7. An agonist with high efficacy but low potency:
• A) Produces low maximal response even at high dose
• B) Requires high dose to reach maximum effect
• C) Binds irreversibly to receptors
• D) Blocks receptor without activation
Rationale: Potency = dose needed for effect (low potency = high dose). Efficacy =
max effect.
8. The therapeutic index (TI) is calculated as:
• A) TD50/ED50 (toxic dose 50 / effective dose 50)
• B) TD50/ED50 is correct but TI usually = LD50/ED50 in animals
• C) ED50/TD50
• D) Cmax/Tmax
Rationale: TI = LD50/ED50 (preclinical) or TD50/ED50 (clinical). Narrow TI =
low safety margin (e.g., digoxin, warfarin).
9. Enterohepatic recirculation results in:
• A) Prolonged drug action due to reabsorption
• B) Complete renal excretion
• C) Reduced plasma protein binding
• D) First-pass metabolism avoidance
Rationale: Drug (e.g., estrogen, morphine) excreted in bile → hydrolyzed in gut
→ reabsorbed → secondary peak plasma level.
10. Which drug is a prodrug requiring hepatic activation (2026 example)?
